VEGFA and neoplasm: The therapeutic blockade of VEGF by bevacizumab in CRC patients induces complex changes in the stromal compartment of the tumour lesion, including the loss of chaotic microvessels, remodelling of the vascular wall and a reduction in the interstitial fluid pressure (Willett et al, 2004).